Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (315)	6/20/2007 1:35:47 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 360

Sure, with the shares off 40% in the past couple months and seemingly in the process of bottoming out, why not? I see VNDA and CRXX added to the index, while glgc was dropped Message 23544154 That might have helped tank the shares. Plus Tartaglia left (but is still an advisor) so that was a negative, possibly helping to drag the shares down. If something I follow drops down below book value, I buy some. If it drops to cash/share, I buy more. That said, I don't have a very big position. Although there might be enough time to take this up over the next month-- then you have earnings report to deal with. That's always ugly. I plan to add to my position then, heck, it could trade down another 30% from here if the market turns really ugly and they show another 10M of burn next report (ultimate low of a buck a share?). I don't expect to put more than a couple or three percent of my worth into it. I will remain Cashboy <g>. I'd much rather know what Tuck and Rick are buying, but that would not be as fun as speculating on my own. fyi--Melior actually has stuff that made the cut meliordiscovery.com KineMed's website kinemed.com Accomplishments KineMed's indications discovery program has been remarkably successful. In 2006, we discovered novel therapeutic activities for four compounds. Two are in preclinical assessment. Two are lead candidates for treatment of ALS/Parkinson's disease. We also have completed or are currently involved in 29 pharma programs across four disease states with 14 companies.